341 related articles for article (PubMed ID: 34090865)
21. Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision.
Sahakyan N; Haddad A; Richardson S; Forcha-Etieundem V; Christopher L; Alharbi H; Campbell R
Anticancer Agents Med Chem; 2017; 17(8):1033-1039. PubMed ID: 28042778
[TBL] [Abstract][Full Text] [Related]
22. Biological rationale for the design of polymeric anti-cancer nanomedicines.
Zhou Y; Kopeček J
J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
[TBL] [Abstract][Full Text] [Related]
23. Tumor microenvironment-regulating nanomedicine design to fight multi-drug resistant tumors.
Xu Q; Lan X; Lin H; Xi Q; Wang M; Quan X; Yao G; Yu Z; Wang Y; Yu M
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023 Jan; 15(1):e1842. PubMed ID: 35989568
[TBL] [Abstract][Full Text] [Related]
24. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
25. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
26. Impact of cancer metabolism on therapy resistance - Clinical implications.
Gonçalves AC; Richiardone E; Jorge J; Polónia B; Xavier CPR; Salaroglio IC; Riganti C; Vasconcelos MH; Corbet C; Sarmento-Ribeiro AB
Drug Resist Updat; 2021 Dec; 59():100797. PubMed ID: 34955385
[TBL] [Abstract][Full Text] [Related]
27. Carrier-Free Nanomedicine for Cancer Immunotherapy.
Fu Y; Bian X; Li P; Huang Y; Li C
J Biomed Nanotechnol; 2022 Apr; 18(4):939-956. PubMed ID: 35854464
[TBL] [Abstract][Full Text] [Related]
28. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
[TBL] [Abstract][Full Text] [Related]
29. Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics.
Overchuk M; Zheng G
Biomaterials; 2018 Feb; 156():217-237. PubMed ID: 29207323
[TBL] [Abstract][Full Text] [Related]
30. Smart Nanosystems for Overcoming Multiple Biological Barriers in Cancer Nanomedicines Transport: Design Principles, Progress, and Challenges.
Lin G; Zhou J; Cheng H; Liu G
Small; 2023 Jul; 19(28):e2207973. PubMed ID: 36971279
[TBL] [Abstract][Full Text] [Related]
31. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
Martin JD; Cabral H; Stylianopoulos T; Jain RK
Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
[TBL] [Abstract][Full Text] [Related]
32. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
33. Nanoparticles Targeting and Remodeling Tumor Microenvironment for Cancer Theranostics.
Lin G; Chen S; Mi P
J Biomed Nanotechnol; 2018 Jul; 14(7):1189-1207. PubMed ID: 29944095
[TBL] [Abstract][Full Text] [Related]
34. Nanotherapy Targeting the Tumor Microenvironment.
Gong BS; Wang R; Xu HX; Miao MY; Yao ZZ
Curr Cancer Drug Targets; 2019; 19(7):525-533. PubMed ID: 30569855
[TBL] [Abstract][Full Text] [Related]
35. From Passive Targeting to Personalized Nanomedicine: Multidimensional Insights on Nanoparticles' Interaction with the Tumor Microenvironment.
Sebak AA; El-Shenawy BM; El-Safy S; El-Shazly M
Curr Pharm Biotechnol; 2021; 22(11):1444-1465. PubMed ID: 33308126
[TBL] [Abstract][Full Text] [Related]
36. Emulating interactions between microorganisms and tumor microenvironment to develop cancer theranostics.
Jiang T; Yang T; Chen Y; Miao Y; Xu Y; Jiang H; Yang M; Mao C
Theranostics; 2022; 12(6):2833-2859. PubMed ID: 35401838
[TBL] [Abstract][Full Text] [Related]
37. Stimuli-activatable nanomedicines for chemodynamic therapy of cancer.
Wang W; Jin Y; Xu Z; Liu X; Bajwa SZ; Khan WS; Yu H
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1614. PubMed ID: 32011108
[TBL] [Abstract][Full Text] [Related]
38. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.
Sun B; Hyun H; Li LT; Wang AZ
Acta Pharmacol Sin; 2020 Jul; 41(7):970-985. PubMed ID: 32424240
[TBL] [Abstract][Full Text] [Related]
39. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
40. Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine.
Du JZ; Li HJ; Wang J
Acc Chem Res; 2018 Nov; 51(11):2848-2856. PubMed ID: 30346728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
